ArticleThe Journal of clinical endocrinology and metabolism2019
Health-Related Quality of Life in Turner Syndrome and the Influence of Growth Hormone Therapy: A 20-Year Follow-Up.
Article in The Journal of clinical endocrinology and metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- How Does Turner Syndrome Affect Quality of Life? A Systematic Review.Medicina (Kaunas, Lithuania) · 2025Pooled it
- The Effects of Growth Hormone Treatment Beyond Growth Promotion in Patients with Genetic Syndromes: A Systematic Review of the Literature.International journal of molecular sciences · 2024Pooled it
- Clinical practice guidelines for the care of girls and women with Turner syndrome.European journal of endocrinology · 2024Guideline
- [Multiple clinical effects of recombinant human growth hormone therapy].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Review
- Psychiatric disorders and comorbidity in women with Turner Syndrome: a retrospective national cohort study.Translational psychiatry · 2024Article
- Evaluating the relationship between the proportion of X-chromosome deletions and clinical manifestations in children with turner syndrome.Frontiers in endocrinology · 2024Article
- The quality of life and body image disturbances of Turner syndrome patients in Malaysia: a cross-sectional study.BMC women's health · 2023Article
- Work participation in adults with rare genetic diseases - a scoping review.BMC public health · 2023Article
- Neuropsychological and mental health concerns in a multicenter clinical sample of youth with turner syndrome.American journal of medical genetics. Part A · 2023Article
- Normalization of puberty and adult height in girls with Turner syndrome: results of the Swedish Growth Hormone trials initiating transition into adulthood.Frontiers in endocrinology · 2023Article
- Turner syndrome: French National Diagnosis and Care Protocol (NDCP; National Diagnosis and Care Protocol).Orphanet journal of rare diseases · 2022Article
- Health behaviour of women with Turner Syndrome.Acta paediatrica (Oslo, Norway : 1992) · 2021Article
- Socioeconomic status in patients with Turner syndrome.Comprehensive psychoneuroendocrinology · 2021Article
- A value-based healthcare approach: Health-related quality of life and psychosocial functioning in women with Turner syndrome.Clinical endocrinology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextThe factors that affect the health-related quality of life (HRQoL) of women with Turner syndrome (TS) are controversial.
objectiveThe aim was to describe the HRQoL of women with TS with a focus on how given GH treatment and comorbidity influence HRQoL in adulthood and to compare HRQoL of women with TS with that of women in the general population.
designLongitudinal cohort study, up to 20 years.
settingThe Turner Center at the Section for Endocrinology and Department of Reproductive Medicine at Sahlgrenska University Hospital, Gothenburg, Sweden.
participantsWomen with TS (n = 200), age range 16 to 78 years, were included consecutively and monitored every fifth year between 1995 and 2018. Women from the World Health Organization MONItoring of trends and determinants for CArdiovascular disease project were used as reference populations. INTERVENTIONS AND
main outcome measuresHRQoL was measured using the Psychological General Well-Being index and the Nottingham Health Profile. Associations with somatic variables were assessed using longitudinal linear regression models.
resultsHRQoL was not associated with GH treatment in TS in spite of a mean 5.7 cm taller height. HRQoL was only associated with height per se in one of 13 subscales (P < 0.01). HRQoL was negatively affected by higher age, higher age at diagnosis, and hearing impairment in TS. Women with TS reported a similar HRQoL to the reference population.
conclusionsNo association between previous GH treatment and HRQoL was found during the up to 20 years of follow-up in women with TS. HRQoL of women with TS and the reference population was similar.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.